Effect of ferric Carboxymaltose on hypophosphatemia and hyperphosphaturia, and the role of vitamin D supplementation in patients with moderate iron deficiency anemia: A Quasi-interventional study

EFFECT OF FERRIC CARBOXY MALTOSE ON HYPERPHOSPHATURIA AND HYPOPHOSPHATEMIA, AND THE ROLE OF VITAMIN D SUPPLEMENTATION IN PATIENTS WITH MODERATE IRON DEFICIENCY ANEMIA- A QUASI INTERVENTIONAL STUDY

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260630005

Enrollment

Registered

2026-06-30

Start date

2024-10-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia Vitamin D deficiency

Interventions

Participants will receive intravenous ferric Carboxymaltose along with oral vitamin D supplementation according to the study protocol,Participants will receive ferric Carboxymaltose according to the s

Active Comparator Dietary Supplement,No Intervention No treatment

Ferric Carboxymaltose + vitamin D supplementation ,Ferric Carboxymaltose alone

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Adults > 18 yrs 2 Moderate iron deficiency anemia. 3 Planned to receive intravenous ferric carboxymaltose. 4 Able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. CKD stage 4 or 5. 2. Baseline hypophosphatemia. 3. Pregnancy or lactation. 4. Previous IV iron within 3 months. 5. Disorders affecting phosphate metabolism. 6. Current phosphate supplementation. 7. Severe liver disease. 8. Known hypersensitivity to ferric carboxymaltose.

Design outcomes

Primary

Measure	Time frame
Serum phosphate Baseline & at 6 weeks Automated biochemical analyzer (mg/dl),Urine phosphate levels Baseline & 6 weeks Spot urine phosphate ,Vitamin D Baseline Serum 25 hydroxy vitamin D by chemiluminescent immunoassay ,Hemoglobin Baseline SLS method (mg/dl)	—

Secondary

Measure	Time frame
Serum calcium Baseline & at 6 weeks Automated biochemical analyser (mg/dl),Urinary calcium levels Baseline & at 6 weeks Urine spot calcium	—

Countries

India

Contacts

Public ContactSai Nemani

SRM medical college hospital

manasanemani1999@gmail.com04447432855

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026